Olivier MF - Search Results

1

DNA damage-related RNA expression to assess individual sensitivity to ionizing radiation.

Bishay K, Ory K, Olivier MF, Lebeau J, Levalois C, Chevillard S. Bishay K, et al. Among authors: olivier mf. Carcinogenesis. 2001 Aug;22(8):1179-83. doi: 10.1093/carcin/22.8.1179. Carcinogenesis. 2001. PMID: 11470746

2

Bishay K, Ory K, Lebeau J, Levalois C, Olivier MF, Chevillard S. Bishay K, et al. Among authors: olivier mf. Oncogene. 2000 Feb 17;19(7):916-23. doi: 10.1038/sj.onc.1203405. Oncogene. 2000. PMID: 10702800

3

Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-type p53.

Olivier M, Bautista S, Vallès H, Theillet C. Olivier M, et al. Mol Carcinog. 1998 Sep;23(1):1-12. Mol Carcinog. 1998. PMID: 9766432

4

Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures.

Sagne C, Marcel V, Bota M, Martel-Planche G, Nobrega A, Palmero EI, Perriaud L, Boniol M, Vagner S, Cox DG, Chan CS, Mergny JL, Olivier M, Ashton-Prolla P, Hall J, Hainaut P, Achatz MI. Sagne C, et al. Carcinogenesis. 2014 Apr;35(4):807-15. doi: 10.1093/carcin/bgt381. Epub 2013 Dec 11. Carcinogenesis. 2014. PMID: 24336192 Free PMC article.

5

p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter.

Marcel V, Vijayakumar V, Fernández-Cuesta L, Hafsi H, Sagne C, Hautefeuille A, Olivier M, Hainaut P. Marcel V, et al. Oncogene. 2010 May 6;29(18):2691-700. doi: 10.1038/onc.2010.26. Epub 2010 Mar 1. Oncogene. 2010. PMID: 20190805

6

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. Olivier M, et al. Clin Cancer Res. 2006 Feb 15;12(4):1157-67. doi: 10.1158/1078-0432.CCR-05-1029. Clin Cancer Res. 2006. PMID: 16489069

7

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.

Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. Petitjean A, et al. Oncogene. 2007 Apr 2;26(15):2157-65. doi: 10.1038/sj.onc.1210302. Oncogene. 2007. PMID: 17401424 Review.

8

Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines.

Fernández-Cuesta L, Anaganti S, Hainaut P, Olivier M. Fernández-Cuesta L, et al. Breast Cancer Res Treat. 2011 Jan;125(1):35-42. doi: 10.1007/s10549-010-0819-x. Epub 2010 Mar 11. Breast Cancer Res Treat. 2011. PMID: 20221692

9

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.

Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M. Fernandez-Cuesta L, et al. Int J Cancer. 2011 Apr 15;128(8):1813-21. doi: 10.1002/ijc.25512. Int J Cancer. 2011. PMID: 20549698 Free article.

10

Modulation of DNA topoisomerase I activity by p53.

Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle F, Larsen AK, Riou JF. Gobert C, et al. Biochemistry. 1996 May 7;35(18):5778-86. doi: 10.1021/bi952327w. Biochemistry. 1996. PMID: 8639538

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

94 results

Search Page